Berenberg Bank Forecasts Strong Price Appreciation for Smith & Nephew (LON:SN) Stock

Smith & Nephew (LON:SN) had its price objective upped by analysts at Berenberg Bank from GBX 1,100 ($14.79) to GBX 1,300 ($17.48) in a research note issued to investors on Thursday, Marketbeat.com reports. The firm currently has a “hold” rating on the stock. Berenberg Bank’s price objective points to a potential downside of 3.31% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Smith & Nephew from GBX 1,300 ($17.48) to GBX 1,400 ($18.83) and gave the company a “hold” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of Smith & Nephew from GBX 1,357 ($18.25) to GBX 1,438 ($19.34) and gave the company an “overweight” rating in a research note on Wednesday.

Smith & Nephew Trading Up 0.5%

Shares of LON:SN opened at GBX 1,344.50 ($18.08) on Thursday. The company has a market capitalization of £14.74 billion, a P/E ratio of 48.41, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62. The company’s 50 day moving average price is GBX 1,129.06 and its 200-day moving average price is GBX 1,079.76. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.